<DOC>
	<DOCNO>NCT00611494</DOCNO>
	<brief_summary>The purpose study assess gastrointestinal tolerability EC-MPS compare MMF maintenance transplant patient calcineurin inhibitor regimen , require MMF dose reduction 25 % due GI complication . The tested hypothesis EC-MPS treatment superior MMF therapy term tolerability patient EC-MPS formulation able tolerate high dos compare MMF .</brief_summary>
	<brief_title>Gastrointestinal Tolerability MMF v EC-MPS Maintenance Transplant Patients Treated With Calcineurin Inhibitors</brief_title>
	<detailed_description>The use mycophenolate mofetil ( MMF ) combination calcineurin inhibitor ( CNI : tacrolimus cyclosporine ) show improve graft survival renal , cardiac liver transplantation patient . However , use associate significant side effect , include gastrointestinal complication , cause dose reduction , interruption termination therapy . An alternate formulation : enteric coated mycophenolate sodium ( EC-MPS ) design alleviate severity upper gastrointestinal side effect . Several trial detail protocol suggest benefit GI relate health follow conversion MMF EC-MPS , however believe robust data lacking .</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>recipient liver kidney heart lung kidney/pancreas transplant least 1 month post solid organ transplant immunosuppressive regimen include MMF combination cyclosporine A tacrolimus previous MMF dose reduction minimum 25 % total dose due least one gastrointestinal complication MMF therapy age 1875 year less 1 month post transplant allergy ( hypersensitivity ) MPA , MMF , ECMPS ingredients Myfortic CellCept unwillingness inability give write consent pregnant nursing woman , woman plan become pregnant patient GI symptom due reason related MMF therapy active Post Transplant Lymphoproliferative Disease ( PTLD ) significant uncontrolled concomitant infection serious medical problem active bacterial , viral fungal infection inability selfadminister Quality Life questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Drug tolerance</keyword>
	<keyword>Quality Life</keyword>
</DOC>